The role and advances of immunomodulator therapy for inflammatory bowel disease

Research output: Contribution to journalReviewResearchpeer-review

Immune modulating drugs such as thiopurines (azathioprine and 6-mercaptopurine) and methotrexate has been a mainstay for treatment of inflammatory bowel disease (IBD) for decades. However, despite widely used in IBD, questions still remain concerning the most rational treatment regimens of these agents. Results from a range of recent studies necessitate increased awareness on how to best use these potent drugs in the clinic. As controversy still remains regarding the most appropriate use of immunomodulators, this review is based on scrutinizing the current literature, with emphasis on randomized controlled trials and Cochrane reviews, focusing on aspects that can lead to optimal and evidence-based thiopurine and methotrexate treatment strategies in IBD.

Original languageEnglish
JournalExpert Review of Gastroenterology & Hepatology
Issue number2
Pages (from-to)177-189
Number of pages13
Publication statusPublished - 2015

    Research areas

  • 6-Mercaptopurine, Azathioprine, Humans, Immunologic Factors, Immunomodulation, Inflammatory Bowel Diseases, Methotrexate, Treatment Outcome

ID: 152248146